      Document 0068
 DOCN  DRG0068
 UNIQUE IDENTIFIER        DRG-0179
 NAME OF SUBSTANCE        882C87 [FDA 130A]
 STANDARD CHEMICAL NAME   1-(beta-D-arabinofuranosyl)-5-(1-propynyl)ura-
                          cil [FDA 130A]
 SYNONYMS                 BW882C87 [AmFAR Tx Dir 1995;7(4)]
 PROTOCOL ID NUMBERS      FDA 130A
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: In vitro activity against
                          varicella zoster virus (VZV). Data from
                          pharmacokinetic studies in HIV negative
                          volunteers suggest that potential therapeutic
                          concentrations can be achieved with once
                          daily dosing; elimination is mostly renal.
                          [AmFAR Tx Dir 1993;6(4)] [AmFAR Tx Dir
                          1995;7(4)]
 DISEASES STUDIED/TREATED Treatment of localized herpes zoster [FDA
                          130A] [AmFAR Tx Dir 1995;7(4)]
 CLASSIFICATION CODE      Antiviral [FDA 130A]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: A nucleoside analog [AmFAR
                          Tx Dir 1993;6(3)]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Oral. [AmFAR Tx Dir
                          1995;7(4)]
 SUBSTANCE DELIVERY DATA  DOSAGE: 200 mg tablets. [FDA 130A]
 MANUFACTURERS            Glaxo Wellcome
 REFERENCES               Andrei G, Snoeck R, Reymen D, Liesnard C,
                          Goubau P, Desmyter J, De Clercq E.
                          Comparative activity of selected antiviral
                          compounds against clinical isolates of
                          varicella-zoster virus. Eur J Clin Microbiol
                          Infect Dis 1995 Apr;14(4):318-29.
 REFERENCES               Peck RW, Wootton R, Lee DR, Jackson SH,
                          Posner J. The bioavailability and disposition
                          of
                          1-(beta-D-arabinofuranosyl)-5-(1-propynyl)ura-
                          cil (882C87), a potent, new anti-varicella
                          zoster virus agent. Br J Clin Pharmacol 1995
                          Feb;39(2):143-9.
 REFERENCES               Peck RW, Weatherley BC, Wootton R, Crome P,
                          Posner J, et al. Pharmacokinetics and
                          tolerability of single oral doses of 882C87,
                          a potent, new anti-varicella-zoster virus
                          agent, in healthy volunteers. Antimicrob.
                          Agents Chemother.; VOL 39 ISS Jan 1995,
                          P20-27, (REF 9).
 REFERENCES               Gnann JW Jr. New antivirals with activity
                          against varicella-zoster virus. Ann Neurol.
                          1994;35 Suppl:S69-72.
 REFERENCES               Darby G. Acyclovir--and beyond. J Int Med
                          Res. 1994;22 Suppl 1:33A-42A.
 REFERENCES               Wood MR, McKendrick MW, Bannister B, Mandal
                          BK, Peck RW, Crooks RJ. Preliminary
                          pharmacokinetics and safety of 882C87 in
                          patients with herpes zoster. J Med Virol.
                          1993;Suppl 1:154-7.
 REFERENCES               Darby G. The acyclovir legacy: its
                          contribution to antiviral drug discovery. J
                          Med Virol 1993;Suppl 1:134-8.
 ENTRY MONTH              9306
 LAST REVISION DATE       960612
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
